This segment focuses on the research and development of in vivo gene editing medicines for cardiovascular diseases. Verve Therapeutics utilizes CRISPR-based gene editing technology and lipid nanoparticles (LNPs) for targeted delivery to the liver. The primary focus is on permanently turning off genes like PCSK9 and ANGPTL3 to reduce LDL cholesterol and the risk of heart disease. Research and development activities include preclinical studies, clinical trials (e.g., the ongoing Heart-2 trial for VERVE-102), and manufacturing process development. The company aims to address the significant unmet medical need in cardiovascular disease, offering a potential one-time treatment option. Market positioning is as a pioneer in the field of gene editing for cardiovascular disease, with collaborations with companies like Lilly and Vertex. Future opportunities include expanding the pipeline to address other cardiovascular targets and indications. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy. Partnerships with companies like Beam Therapeutics and Acuitas Therapeutics support technology access and development efforts.